Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks

Executive Summary

The broad labeling that FDA approved for Benlysta, the breakthrough lupus drug Human Genome Sciences Inc. shares with GlaxoSmithKline PLC, could position the biologic for widespread reimbursement.
Advertisement

Related Content

Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn
HGS Wastes No Time Investing In Pipeline Beyond Benlysta
Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard
Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
Variety of Issues Undermine Efficacy Data As FDA Takes Benlysta To Advisory Panel
Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims

Topics

Advertisement
UsernamePublicRestriction

Register

PS053200

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel